Lexicon Pharmaceuticals, Inc. (LXRX) Successfully Completes Phase 1b Trials for LX1032
Source: http://Blog.QualityStocks.net/?p=13854Posted on Friday, November 14th, 2008 | In Small & Micro Cap
Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on developing breakthrough treatments for a variety of human diseases, recently announced that it successfully completed a second Phase 1 clinical trial of LX1032. The drug candidate will be used by patients to manage gastrointestinal symptoms associated with carcinoid syndrome, which is a chronic condition that results in metastatic neuroendocrine tumors that secrete large amounts of serotonin.
During the Phase 1b multiple ascending-dose trial, the LX1032 was found to be well-tolerated at all dosage levels by all 40 volunteers. Five doses were given to the participants ranging from 100 mg to a maximum dosage of 1500 mg over a 14-day period. Analysis of the data found that LX1032 significantly reduced blood serotonin levels and urinary 5-HIAA, a market of serotonin biosynthesis. No serious adverse effects were reported by the volunteers of the trial.
“The substantial reduction in serotonin observed in this study confirms our preclinical observations and suggests potent inhibition of peripheral serotonin production,” said Philip Brown, Senior Vice President at Lexicon. “We are eager to test the compound in patients with carcinoid syndrome who suffer from significant gastrointestinal symptoms relating to the overproduction of serotonin.”
Lexicon has plans to move forward and initiate a Phase 2 study focusing on patients with carcinoid syndrome. In June 2008, the FDA gave LX1032 a Fast Track designation that facilitates the development of the drug and expedites the review of the drug. LX1032 will be the third drug candidate developed by Lexicon that has successfully moved into Phase 2 clinical trials.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
- Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
- Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
- Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
- Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009
Biopharmaceutical, carcinoid;, Fda, Lexicon Pharmaceuticals Inc.;, LX1032;, Neuroendocrine Tumors, Philip Brown;, Small & Micro Cap
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.